Publications
Found 2 results
Filters: Author is T. Isbir [Clear All Filters]
“Cox-2 gene polymorphism and IL-6 levels in coronary artery disease”, vol. 10, pp. 810-816, 2011.
, Antman EM, DeMets D and Loscalzo J (2005). Cyclooxygenase inhibition and cardiovascular risk. Circulation 112: 759-770.
doi:10.1161/CIRCULATIONAHA.105.568451
PMid:16061757
Barrett-Connor EL, Cohn BA, Wingard DL and Edelstein SL (1991). Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 265: 627-631.
doi:10.1001/jama.265.5.627
Belton O, Byrne D, Kearney D, Leahy A, et al. (2000). Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102: 840-845.
PMid:10952950
Biondi-Zoccai GG, Abbate A, Liuzzo G and Biasucci LM (2003). Atherothrombosis, inflammation, and diabetes. J. Am. Coll. Cardiol. 41: 1071-1077.
doi:10.1016/S0735-1097(03)00088-3
Cipollone F, Prontera C, Pini B, Marini M, et al. (2001). Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104: 921-927.
doi:10.1161/hc3401.093152
PMid:11514380
Cipollone F, Fazia M, Iezzi A, Zucchelli M, et al. (2003). Suppression of the functionally coupled cyclooxygenase-2/ prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107: 1479-1485.
doi:10.1161/01.CIR.0000056530.03783.81
PMid:12654603
Davis SN, Granner DK, Hardman JG and Limbird LE (2006). Insulin, Oral Hypoglycemic Agents and Pharmacology of Endocrin Pancreas - Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 11th edn. The McGraw-Hill Companies Inc., New York.
Gilroy DW, Colville-Nash PR, Willis D, Chivers J, et al. (1999). Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5: 698-701.
doi:10.1038/9550
PMid:10371510
Hegener HH, Diehl KA, Kurth T, Gaziano JM, et al. (2006). Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J. Thromb. Haemost. 4: 1718-1722.
doi:10.1111/j.1538-7836.2006.02054.x
PMid:16879213
Huuskonen KH, Kunnas TA, Tanner MM, Mikkelsson J, et al. (2008). COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study. Mediators Inflamm. 2008: 289453.
doi:10.1155/2008/289453
PMid:18385811 PMCid:2276816
Kohsaka S, Volcik KA, Folsom AR, Wu KK, et al. (2008). Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196: 926-930.
doi:10.1016/j.atherosclerosis.2007.02.010
PMid:17350020
Kosaka T, Miyata A, Ihara H, Hara S, et al. (1994). Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem. 221: 889-897.
doi:10.1111/j.1432-1033.1994.tb18804.x
PMid:8181472
Laakso M, Voutilainen E, Sarlund H, Aro A, et al. (1985). Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics. Atherosclerosis 56: 271-281.
doi:10.1016/0021-9150(85)90003-6
Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
doi:10.1093/nar/16.3.1215
PMid:3344216 PMCid:334765
Orbe J, Beloqui O, Rodriguez JA, Belzunce MS, et al. (2006). Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin. Chim. Acta 368: 138-143.
doi:10.1016/j.cca.2005.12.019
PMid:16458279
Papafili A, Hill MR, Brull DJ, McAnulty RJ, et al. (2002). Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol. 22: 1631-1636.
doi:10.1161/01.ATV.0000030340.80207.C5
PMid:12377741
Paramo JA, Rodriguez JA, Beloqui O and Orbe J (2005). Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis? Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 303-311.
doi:10.2174/1568006054553381
Pisetsky DS and St. Clair EW (2001). Progress in the treatment of rheumatoid arthritis. JAMA 286: 2787-2790.
doi:10.1001/jama.286.22.2787
Prescott SM and Fitzpatrick FA (2000). Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta 1470: M69-M78.
PMid:10722929
Rudock ME, Liu Y, Ziegler JT, Allen SG, et al. (2009). Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the diabetes heart study. Atherosclerosis 203: 459-465.
doi:10.1016/j.atherosclerosis.2008.07.018
PMid:18768181 PMCid:2699582
Schonbeck U, Sukhova GK, Graber P, Coulter S, et al. (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155: 1281-1291.
doi:10.1016/S0002-9440(10)65230-3
Sjöholm A and Nyström T (2005). Endothelial inflammation in insulin resistance. Lancet 365: 610-612.
PMid:15708106
World Health Organization (WHO) (1999). Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications - Report of a WHO (World Health Organization) Consultation. World Health Organization, Geneva.
Yokoyama C and Tanabe T (1989). Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun. 165: 888-894.
doi:10.1016/S0006-291X(89)80049-X
“CCR2-64I is a risk factor for development of bladder cancer”, vol. 9, pp. 685-692, 2010.
, Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, et al. (2002). Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J. Am. Soc. Nephrol. 13: 754-758.
PMid:11856781
Amann B, Perabo FG, Wirger A, Hugenschmidt H, et al. (1998). Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br. J. Urol. 82: 118-121.
http://dx.doi.org/10.1046/j.1464-410x.1998.00675.x
PMid:9698673
Balkwill F (2004). Cancer and the chemokine network. Nat. Rev. Cancer 4: 540-550.
http://dx.doi.org/10.1038/nrc1388
PMid:15229479
Barrett JC, Fry B, Maller J and Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
http://dx.doi.org/10.1093/bioinformatics/bth457
PMid:15297300
Coelho A, Matos A, Catarino R, Pinto D, et al. (2005). Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol. Oncol. 96: 760-764.
http://dx.doi.org/10.1016/j.ygyno.2004.11.028
PMid:15721423
Dawson SJ, Morris PJ and Latchman DS (1996). A single amino acid change converts an inhibitory transcription factor into an activator. J. Biol. Chem. 271: 11631-11633.
http://dx.doi.org/10.1074/jbc.271.20.11631
PMid:8662774
Ginestier C, Liu S, Diebel ME, Korkaya H, et al. (2010). CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest 120: 485-497.
http://dx.doi.org/10.1172/JCI39397
PMid:20051626 PMCid:2810075
Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, et al. (2001). Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann. Intern. Med. 135: 782-795.
http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00008
PMid:11694103
Jensen OM, Esteve J, Moller H and Renard H (1990). Cancer in the European Community and its member states. Eur. J. Cancer 26: 1167-1256.
http://dx.doi.org/10.1016/0277-5379(90)90278-2
Kantor AF, Hartge P, Hoover RN, Narayana AS, et al. (1984). Urinary tract infection and risk of bladder cancer. Am. J. Epidemiol. 119: 510-515.
PMid:6711540
Karnoub AE and Weinberg RA (2006). Chemokine networks and breast cancer metastasis. Breast Dis. 26: 75-85.
PMid:17473367
Kaufman DS, Shipley WU and Feldman AS (2009). Bladder cancer. Lancet 374: 239-249.
http://dx.doi.org/10.1016/S0140-6736(09)60491-8
Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, et al. (1998). A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat. Med. 4: 350-353.
http://dx.doi.org/10.1038/nm0398-350
PMid:9500612
Luster AD (1998). Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338: 436-445.
http://dx.doi.org/10.1056/NEJM199802123380706
PMid:9459648
Mackay CR (1997). Chemokines: what chemokine is that? Curr. Biol. 7: R384-R386.
http://dx.doi.org/10.1016/S0960-9822(06)00181-3
Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
http://dx.doi.org/10.1093/nar/16.3.1215
PMid:3344216 PMCid:334765
Miyagishi R, Niino M, Fukazawa T, Yabe I, et al. (2003). C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J. Neuroimmunol. 145: 135-138.
http://dx.doi.org/10.1016/j.jneuroim.2003.09.003
PMid:14644039
Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, et al. (2003). Effects of CCR5-Delta32 and CCR2-64I alleles on HIV- 1 disease progression: the protection varies with duration of infection. AIDS 17: 377-387.
http://dx.doi.org/10.1097/00002030-200302140-00012
PMid:12556692
Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, et al. (2004). A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 18: 729-738.
http://dx.doi.org/10.1097/00002030-200403260-00003
PMid:15075507
Navratilova Z (2006). Polymorphisms in CCL2 & CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 150: 191-204.
http://dx.doi.org/10.5507/bp.2006.028
PMid:17426779
Rollins BJ (1997). Chemokines. Blood 90: 909-928.
PMid:9242519
Rossi D and Zlotnik A (2000). The biology of chemokines and their receptors. Annu. Rev. Immunol. 18: 217-242.
http://dx.doi.org/10.1146/annurev.immunol.18.1.217
PMid:10837058
Rovin BH, Lu L and Saxena R (1999). A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem. Biophys. Res. Commun. 259: 344-348.
http://dx.doi.org/10.1006/bbrc.1999.0796
PMid:10362511
Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, et al. (2010). The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 105: 300-308.
http://dx.doi.org/10.1111/j.1464-410X.2009.09076.x
PMid:19912200
Smith MW, Carrington M, Winkler C, Lomb D, et al. (1997). CCR2 chemokine receptor and AIDS progression. Nat. Med. 3: 1052-1053.
http://dx.doi.org/10.1038/nm1097-1052c
PMid:9334699
Struyf S, Proost P and Van Damme J (2003). Regulation of the immune response by the interaction of chemokines and proteases. Adv. Immunol. 81: 1-44.
http://dx.doi.org/10.1016/S0065-2776(03)81001-5
Szalai C, Duba J, Prohaszka Z, Kalina A, et al. (2001). Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 158: 233-239.
http://dx.doi.org/10.1016/S0021-9150(01)00423-3
Vandercappellen J, Van Damme J and Struyf S (2008). The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267: 226-244.
http://dx.doi.org/10.1016/j.canlet.2008.04.050
PMid:18579287
Vázquez-Lavista LG, Lima G, Gabilondo F and Llorente L (2009). Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology 74: 414-418.
http://dx.doi.org/10.1016/j.urology.2009.04.016
PMid:19646633
Vicari AP and Caux C (2002). Chemokines in cancer. Cytokine Growth Factor Rev. 13: 143-154.
http://dx.doi.org/10.1016/S1359-6101(01)00033-8
Yoshie O, Imai T and Nomiyama H (2001). Chemokines in immunity. Adv. Immunol. 78: 57-110.
http://dx.doi.org/10.1016/S0065-2776(01)78002-9
Zafiropoulos A, Crikas N, Passam AM and Spandidos DA (2004). Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J. Med. Genet. 41: e59.
http://dx.doi.org/10.1136/jmg.2003.013649
PMid:15121787 PMCid:1735773